Product Information
SB273005 is a monoclonal antibody that binds to all-trans retinoic acid (ATRA) and prevents it from binding to ATRA receptors. This binding inhibits the production of growth factor-β1, collagen, and ATP in tumor cells. SB273005 has been shown to be effective in treating patients with glioma, as it decreases the size of tumors and prolongs survival time. The efficacy of SB273005 has also been demonstrated in tissue culture experiments on mouse glioma cells. The monoclonal antibody is administered intravenously by infusion over a period of 30 minutes each week for 3 weeks.
Chemical properties
Technical inquiry about: 3D-FIA67831 SB273005
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
